$0

Allogene’s R&D Showcase 2022: Celltelligence Analysis – Part 2

On Tuesday, November 29, Allogene held an R&D showcase (press release / presentation) featuring the advances in its hematology and solid tumor programs. Below, Celltelligence provides part 2 of its analysis on Allogene’s pipeline covering its expanded solid tumor franchise and initial clinical data from ALLO-316’s (allogeneic CD70 CAR-T) while comparing Allogene’s Dagger platform to other approaches for reducing immune rejection.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.